Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Hyperpolarized 1-13C -Pyruvate Clear all

Conditions: Breast Neoplasms
Interventions: Formal study using hyperpolarized 13C-pyruvate injection, Feasible study using hyperpolarized 13C-pyruvate injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Meningioma
Interventions: Hyperpolarized carbon C 13 pyruvate, Magnetic Resonance Image (MRI), Saline; Drug · Procedure · Other
Lead sponsor: Charlie Wang, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Thoracic Cancer, Left Sided Breast Cancer
Interventions: [1-13C]pyruvate along with MRI imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: High Risk Prostate Carcinoma, Prostate Cancer
Interventions: Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT); Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC)
Interventions: Hyperpolarized 1-13C -Pyruvate; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions: HP 13C pyruvate injection, MRI Scanner; Drug · Device
Lead sponsor: Ari Green; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioma
Interventions: Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Hyperpolarized Pyruvate (13C) injection; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized 13C-pyruvate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumor
Interventions: Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea; Drug · Procedure
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: Hyperpolarized [13C] Pyruvate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Traumatic Brain Injury, Subarachnoid Hemorrhage
Interventions: Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Interventions: Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging; Other · Drug · Procedure
Lead sponsor: Daniel M. Spielman; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging; Drug · Procedure
Lead sponsor: Susan Chang; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Pyruvate (13C), MRI; Drug · Device
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging); Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: Pyruvate (13C), MRI; Drug · Device
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Pyruvate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme
Interventions: Hyperpolarized Pyruvate (13C), Magnetic Resonance Spectroscopic Imaging (MRSI); Drug · Procedure
Lead sponsor: Susan Chang; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy; Drug · Radiation · Procedure + 1 more
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Thyroid Gland Carcinoma
Interventions: Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

DNP-MRSI of HCC Metabolism to Predict Therapeutic Response

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer

UTSW HP [13-C] Pyruvate Injection in HCM

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

MRI With C13 Pilot Study Prostate Cancer

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy